The Early and Late Contribution of Fasting and Postprandial Triglycerides on Newborn Subcutaneous and Intrahepatic Fat in Pregnancy
University of Colorado, Denver · NCT04394806
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 0 mo–39 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 140
- US sites recruiting
- 1
- Study start
- March 1, 2022
- Record last updated
- May 12, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study plans to learn more about how triglyceride levels in pregnancy affect newborn fat mass. Obesity in pregnancy, in the absence of gestational diabetes, is now the most common cause of large-for-gestational-age infants and increased newborn fat mass. Previous data supports the idea that maternal triglycerides, not glucose, are the strongest predictor of both total newborn fat mass and liver fat. In this study, mothers will monitor triglyceride and glucose levels at specific points in pregnancy using point-of-care meters at home. Two weeks after birth, infants will have total fat measured by air-displacement plethysmography (PEAPOD) and liver fat measures by Magnetic Resonance Spectroscopy (MRS). The central hypothesis is that in obesity, fasting triglycerides and postprandial triglycerides will predict newborn fat mass in a free-living environment.
Conditions: Pregnancy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Pregnant women less than 16 weeks gestational age
- Between the ages of 21-39 years
- Pre-pregnancy BMI 28-39 kg/m2
Exclusion Criteria
- Pre-gestational diabetes or prediabetes
- History of gestational diabetes
- History of pre-eclampsia, spontaneous pre-term delivery, or gestational hypertension \<34wks
- Tobacco or illicit substance use
- Chronic steroid use
Recruiting US locations
University of Colorado/Anschutz Medical Campus
Aurora, CO 80045
Site contact: Emily Dunn, MS, RDN · 303-724-0320 · Emily.2.Dunn@cuanschutz.edu
Study contacts (from the official record)
- Emily Z Dunn, MS, RDN · 303-724-0320 · Emily.2.Dunn@cuanschutz.edu
- Nicole Hirsch, MS · 303-724-0572 · Nicole.Hirsch@cuanschutz.edu
Similar studies in Colorado
All weight loss studies in Colorado →- RecruitingHealthy volunteersPhase 1
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
University of Colorado, Denver
- Location
- Aurora, CO
- Eligibility basics
- Ages 19–37 · Women only
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- Arvada, CO + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company
- Location
- Lakewood, CO + 17 other US sites
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Aurora, CO + 59 other US sites
- Eligibility basics
- Ages 18+